

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Sanai Health Industry Group Company Limited

三愛健康產業集團有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1889)

POSITIVE PROFIT ALERT

This announcement is made by Sanai Health Industry Group Company Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571, Laws of Hong Kong).

The board (the “**Board**”) of directors (the “**Directors**”) of the Company wishes to inform the shareholders (the “**Shareholders**”) of the Company and potential investors that, based on the latest available information and the preliminary review of the unaudited consolidated management accounts of the Group for the year ended 31 December 2021, it is expected that the Group will record a gross profit of not less than RMB40 million for the year ended 31 December 2021, as compared to approximately RMB31 million for the corresponding period in 2020 and will record a net profit attributable to the owners of the Company of approximately RMB9 million for the year ended 31 December 2021 as compared to approximately RMB6 million for the year ended 31 December 2020.

The Board considers that the increase in gross profit and net profit attributable to the owners of the Company for the year ended 31 December 2021 was mainly attributable to (i) the increase in sales of self-manufactured pharmaceutical products with relatively high gross profit margin; and (ii) the increase in interest income derived from finance leasing business.

The information in this announcement is only based on the preliminary assessment by the management of the Company after reviewing and considering the unaudited consolidated result of the Group. Information in this announcement has not been audited by the auditors of the Company. The audited consolidated annual results of the Group for the year ended 31 December 2021 have not yet been finalized. Therefore, the actual results of the Group for the year ended 31 December 2021 may differ from the information contained in this announcement. Shareholders and potential investors should refer to the annual results announcement of the Group for the year ended 31 December 2021 which is expected to be published on 29 March 2022, for details of the performance of the Group.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
Sanai Health Industry Group Company Limited
Chen Chengqing
Chairman

Hong Kong, 25 March 2022

As at the date of this announcement, the Board comprises five executive directors, namely, Mr. Chen Chengqing (Chairman), Mr. Gao Borui, Mr. Yuan Chaoyang, Professor Zhang Rongqing and Mr. She Hao, one non-executive director, namely, Mr. Xiu Yuan and three independent non-executive directors, namely, Professor Zhu Yi Zhun, Mr. Khor Khie Liem Alex and Mr. Zhang Ruigen.